



Press Release

Type 1 Diabetes Program by RSSDI supported by Sanofi's Social Impact Initiative delivering positive outcomes

September 26, 2023. Research Society for the Study of Diabetes in India (RSSDI) supported by Sanofi India Limited (SIL) have shared that their social impact collaboration for Type 1 diabetes (T1D) program which is helping to deliver positive outcomes to reduce hypoglycemia and hyperglycemia, is resulting in improved care and diagnosis. The program has created a universal standard-of-care for the diagnosis and management of this auto-immune chronic condition, which impacts the pediatric population and young adults. The program includes funding for free insulin, syringes, lancets, and glucose strips to 1,300 underprivileged children living with this condition.

These 1300 children are receiving better education on T1D management. Over the last 9-months (September 2022 to June 2023), the program's intervention has reduced the number of children experiencing **hypoglycaemia** (1 to 4 times per week) **by 46%** (vs. 70%) and children experiencing **hyperglycaemia** (1 to 4 times per week) **by 25%** (vs. 52%).

Of the 1300 children living with Type 1 diabetes and enrolled in this social impact program across India, 69 children are from Maharashtra.

Referred to as juvenile or insulin-dependent diabetes, people living with Type 1 diabetes and their caregivers in India continue to face challenges in diabetes management. This is because there are very few dedicated doctors and educators trained to treat and manage T1D. Other challenges are poor public awareness about T1D, the socio-economic burden, and access to proper healthcare facilities, particularly in semi-urban and rural areas. Other complexities include delayed diagnosis, poor cold-chain management for insulin, and insufficient education for patients and caregivers. Furthermore, it is also observed that Type 1 diabetes results in social isolation, particularly for girls. Through this social impact program, we are spreading awareness amongst healthcare providers to join us and help promptly diagnose T1D, so that 3 years of healthy life per person¹ can be restored. Similarly, a provision of access to insulin, test strips and good self-management, could help restore 21.2 years of healthy life per person².

¹ Healthy years lost = an estimate of the time lost to ill-health, disability, or early death from living with T1D. (<https://www.t1dindex.org/countries/india/>)

², <https://www.t1dindex.org/countries/india/>

Hence, RSSDI, India's leading research organization for diabetes, and Sanofi India joined hands in January 2021 for a three-year social impact program to improve the standard-of-care for timely and better diabetes management in children and young adults. People-to-People Health Foundation (PPHF) is the implementing partner for this social impact program.

Dr. Brij Makkar President

MD FIAMS, FICP, FRCP (Glasg,Edin), FACP (USA), FACE (USA), FRSSDI
President - Research Society for the Study of Diabetes in India (RSSDI)

“With an estimated 8.6 lakh T1D patients in India³, we cannot afford to overlook the urgent needs of children living with this condition. By equipping healthcare professionals and educators with the necessary tools and knowledge, the program is enabling timely diagnosis and appropriate diabetes management required for the children to thrive.”

Dr. Sanjay Agarwal

MD, FACE, FACP

Secretary – Research Society for the Study of Diabetes in India (RSSDI)

“For this program, RSSDI and Sanofi India are combining their respective experience and expertise to create a universal standard-of-care that provides access to treatment across India as per global recommendations. RSSDI is dedicated to transforming the landscape of T1D care in India.”

As per the global Type 1 diabetes Index, in India T1D is growing at 6.7% each year compared with 4.4% for Type 2 diabetes.⁴

This Social Impact Program for Type 1 Diabetes by RSSDI supported by Sanofi India Limited is aimed at improving the health status of T1D patients by creating a support program through a network of both trained healthcare professionals (HCPs) and T1D educators across India. Training doctors will enable correct diagnosis and management, leading to reduction in the occurrence of chronic complications. RSSDI has created two sets of modules to build capacity amongst doctors for timely diagnosis of T1D, and for T1D educators in care and management skills for those affected by T1D and their caregivers.

Ms. Aparna Thomas

Senior Director, Corporate Communications and Corporate Social Responsibility, Sanofi India Limited

“We are hugely motivated to see the impact of our social program's intervention that is very quickly improving the quality of life in so many children living with Type 1 diabetes in India. The program is designed to create the standard-of-care that is much needed in Type 1 diabetes for its diagnosis,

³ <https://www.t1dindex.org/countries/india/>

⁴ <https://www.t1dindex.org/countries/india/>

education, and counselling. The program facilitates T1D training to increase the number of doctors and educators and in turn, access to T1D diagnosis, treatment, and care. Sanofi India's social impact program also provides funds for free insulin to 1300 children who need the financial support to access treatment to manage their T1D optimally."

Dr. Archana Sarda

(M.D.) Diabetologist

"Like Type 2 diabetes, Type 1 diabetes is also experiencing an upward trend and while the prevalence may not be as significant, it is still a cause for alarm. Thus, comprehensive training and education on treatment, monitoring, dosage, and titration is crucial in addressing the challenges faced by children with Type 1 diabetes. By equipping healthcare professionals and educators in Maharashtra with the necessary tools and knowledge, we can make a significant difference in the lives of these children."

To learn more about coping with Type 1 diabetes better and bust deep-rooted myths about it, visit:

[Type 1 Diabetes Videos | RSSDI](#)

About RSSDI

Research Society for the Study of Diabetes in India was registered under the Societies Registration Act, XXI of 1860 by the Registrar of Societies, Delhi Administration vide Certificate No. s 5480 of 1972-73 dated July 29, 1972 at Delhi. Currently with close to 12,000 members represented from 21 Indian States and Union Territories, RSSDI is the largest organization in India and South Asia; and one of the largest organizations amongst the top in the world, representing diabetes care. Present across all states in India, RSSDI is supported by 23 state chapters. RSSDI conducts initiatives for improving diabetes care, patient awareness programs, education provision of healthcare facilities, training of educators and doctors who want to work in the field of diabetes. The body supports research through grants to further the understanding of the disease in the Indian population. RSSDI collaborates with a number of organizations who are involved in technology, NGOs, knowledge partners, and within the industry. Through these partnerships, RSSDI does capacity building to reach out to patients, doctors, and healthcare providers to bring them in one ecosystem to implement the healthcare as per recommendations.

Sanofi – in India for India

Sanofi operates in India through two local entities, namely *Sanofi India Limited* and *Sanofi Healthcare India Pvt. Limited*. One of India's most admired healthcare companies, we produce high quality products, have strong ethical values, run social impact programs (primarily in Type 1 diabetes and rare diseases), and have employee programs that enable professional growth, and a culture where our employees have camaraderie and share their passion for excellence. Since 1956, Sanofi has earned the trust as well as a place in 1-in-3 Indian households (if not more). Our world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi India has been recognized by the 'Top® Employers Institute' for 5 years in a row (since 2019).

Visit us at www.sanofi.in and www.sanofiindia.com, or connect with us on [LinkedIn](#) and [Twitter](#).

* Indian Pharma Market as per IQVIA data MAT Dec'22

Media Relations

Aparna Thomas | aparna.thomas@sanofi.com

Vinifer Gandhi | vinifer.gandhi@sanofi.com

Agency Partner

Kritika Khatwani | kritika.khatwani@adfactorspr.com